We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New COVID-19 Mouth Swab Test Can Be Completed On-Premises in 13-25 Minutes Without Laboratory Involvement

By LabMedica International staff writers
Posted on 18 May 2020
Print article
Image: New COVID-19 Mouth Swab Test (Photo courtesy of GeneMe)
Image: New COVID-19 Mouth Swab Test (Photo courtesy of GeneMe)
GeneMe (Gdańsk, Poland) has developed FRANKD, a fast, scalable and reliable mouth swab test for COVID-19 that is completed on-premises in on average 13-25 minutes with no laboratory involvement.

FRANKD requires less time to produce a result than the gold-standard RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) reference test recommended by the World Health Organization. The test uses a patented enzyme rather than the currently scarce reagents used in RT-PCR tests to rapidly produce a definitive and reliable result. The use of a portable machine analyzer to amplify the virus within the sample ensures high test accuracy. Additionally, testing on-premises by trained staff removes delays and the challenge of getting test samples to lab technicians to process.

Individuals use the secure, free Yoti digital ID app to link themselves to their test. With consent, the digital test result is automatically added into the tested person’s Yoti. Individuals can present or share their tamperproof, verified details with other parties in seconds - including their test result - whether in person or online, with a tap of a button or scan of a QR code.

The test has been independently validated with 100% sensitivity and 100% specificity by the Gdańsk University of Technology and European CE regulatory certification is expected by early June. FRANKD is currently in talks with governments and businesses across Europe to roll out millions of tests over the coming months, enabling key industries to test hundreds of thousands of employees daily, to help understand the spread of the virus and to monitor the infection R factor more accurately. FRANKD is scalable with five million monthly tests expected from August. During June and July, FRANKD tests will be processed using hundreds of existing analyzer machines that are able to handle 90 tests every 30 minutes, although GeneMe expects affordable bespoke machines to be available from August.

“We are extremely pleased with the quality of the FRANKD test and the contribution it will make towards the fight against the coronavirus pandemic and its damaging effects on public health and society,” said Dawid Nidzworski Founder and CEO of GeneMe and developer of FRANKD.

Related Links:
GeneMe

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.